Skip to main content
Clinical Trials/NCT05235919
NCT05235919
Recruiting
Phase 2

Repetitive Transcranial Magnetic Stimulation to Promote Helpful Self-regulatory Behaviour in Children and Youth With Autism Spectrum Disorder

Holland Bloorview Kids Rehabilitation Hospital1 site in 1 country50 target enrollmentSeptember 22, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Holland Bloorview Kids Rehabilitation Hospital
Enrollment
50
Locations
1
Primary Endpoint
Recruitment
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study will evaluate the feasibility of repetitive Transcranial Magnetic Stimulation (rTMS) in Autism Spectrum Disorder (ASD) with self-regulation impairment. Baseline and follow-up participant visits will include behavioral assessments of self-regulation and magnetic resonance imaging (MRI) to determine neurophysiological outcomes before and after rTMS treatment.

Detailed Description

Children and youth with Autism Spectrum Disorder (ASD) often present with co-morbid impairments in self-regulation (e.g., difficulty managing their emotions) resulting in unhelpful regulatory approaches such as disruptive compulsive, aggressive and self-injurious behaviour. There is an urgent need to establish novel, precise and effective interventions that promote self-regulation and reduce disruptive behaviours. This project will collect pilot data on the effects of repetitive TMS in reducing disruptive behaviours in youth with ASD, in order to inform the design of a follow-up full-scale clinical trial. Youth with ASD who experience clinically significant difficulties with self-regulation and disruptive behaviour will be recruited. Participants will be randomized to rTMS or sham rTMS for 3 weeks. The overall feasibility of the trial will be assessed. The effect of rTMS on the brain mechanisms of self-regulation and clinical improvement in disruptive behaviours will also be measured. Neurophysiological outcomes, including changes in regional brain network activity for inhibition of behaviour, will be explored.

Registry
clinicaltrials.gov
Start Date
September 22, 2022
End Date
February 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Deryk Beal

Clinician-Scientist

Holland Bloorview Kids Rehabilitation Hospital

Eligibility Criteria

Inclusion Criteria

  • Children with a diagnosis of autism spectrum disorder and self-regulation impairment or challenges
  • Able to participate in rTMS

Exclusion Criteria

  • Children with autism spectrum disorder but no co-morbid self-regulation disorders.
  • Children with contraindications to TMS (history of seizures, family history of seizures, metal implants)
  • Co-existing neurological conditions (epilepsy, stroke, etc.)

Outcomes

Primary Outcomes

Recruitment

Time Frame: Weeks 1-18

Recruitment rates of 4 participants/month are achieved with a ≥ 20% response rate

Blinding success

Time Frame: Weeks 1-18

Blinding of participants and their parents/caregivers and required study team members will be assessed using a Blinding Questionnaire indicating the perceived group membership (rTMS/sham)

Adherence

Time Frame: Weeks 1-18

90% of participants who complete assessment achieve the target intensity and dose (15 rTMS sessions)

Attrition

Time Frame: Weeks 1-18

Attrition rates of less than 10% (i.e., ≥90% of participants successfully complete assessments).

Secondary Outcomes

  • Clinical Measure of Self-Regulation: The Response To Stress Questionnaire - Family Stress(Weeks 1, 6, 18)
  • Clinical Measure of Self-regulation: Aberrant Behaviour Checklist - Irritability Subscale(Weeks 1, 6, 18)
  • Clinical Measure of Self-regulation: Emotional Regulation Checklist(Weeks 1, 6, 18)
  • Inhibitory control(Weeks 1, 6, 18)
  • Structural brain changes (magnetic resonance imaging)(Weeks 1, 6, 18)
  • Functional brain changes (magnetic resonance imaging)(Weeks 1, 6, 18)
  • Clinical Measure of Self-regulation: Emotion Dysregulation Index Reactivity and Dysphoria(Weeks 1, 6, 18)
  • Overall Clinical Change(Weeks 1, 6, 18)

Study Sites (1)

Loading locations...

Similar Trials